Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

ds and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase), whether any further clinical trials will be required, the actions that may be required of Savient by the FDA in connection with the BLA, the reversion to and revalidation of the Phase 3 manufacturing process, the timing of a resubmission to the FDA in response to the complete response letter and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials, our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... Instrumental in Dickinson Mental Health Center,s Ability ... to Track ... Oct. 18 Netsmart Technologies, Inc.,a leading provider of ... today announced that Netsmart customer,Dickinson Mental Health Center ranked ...
... Elekta, a global leader in radiation,oncology and ... at the 49th Annual Meeting of The American ... reduce,treatment times and increase efficiency. The meeting will ... Los Angeles Convention Center (Los Angeles,California, USA). Elekta ...
... Mass., Oct. 18 Alseres,Pharmaceuticals, Inc. (Nasdaq: ... Frank Bobe,Executive Vice President and Chief Business ... at Windhover Information,s 2nd,Annual Therapeutic Area Partnerships ... will be presenting an overview on Alseres ...
Cached Biology Technology:Netsmart Technologies Customer in Pennsylvania Recognized for Achieving Data Benchmarking Milestones 2Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 2Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 3Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 4Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference 2
(Date:8/27/2014)... easier when it is related to ability that we ... a new melody more easily than learning how to ... Center for the Neural Basis of Cognition (CNBC)a joint ... Universityhave discovered a fundamental constraint in the brain that ... story in the Aug. 28, 2014, issue of ...
(Date:8/27/2014)... DURHAM, N.C. -- When we want to listen carefully ... talking. The second thing we do is stop moving ... unwanted sounds generated by our own movements. , This ... deep in the brain. Indeed, indirect evidence has long ... somehow influences the auditory cortex, which gives rise to ...
(Date:8/27/2014)... giant, frightening beasts. But every creature is a baby ... containing fossils of 24 very young dinosaurs and one ... overseen by a caretaker, according to a new study ... Hedrick and Peter Dodson led the work, collaborating with ... the specimen is held. Hedrick is a doctoral student ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3
... 2012, the prices of corn and soybean meal for ... reduce their costs, pork producers are looking for alternative ... the University of Illinois have developed equations for calculating ... rendering industry. Professor of animal sciences Hans H. ...
... There, the pitch by company CEO John R. Lewandowski, who ... could save one million lives every year with just refrigerator ... on Fortune Magazine/CNN online. The team,s product, based ... a magnetic substance that malaria parasites release when digesting red ...
... USA Geosphere papers posted online 4 ... Swath Mapping), EarthScope, CHIRP (compressed high-intensity radar pulse), and ... understanding of the nature of Earth. New locations studied: ... nation monument, Mxico; and Andalshatten batholith, central Norway. ...
Cached Biology News:Calculating phosphorus and calcium concentrations in meat and bone meal for pig diets 2Hand-held device cheaply, quickly diagnosis malaria 2Hand-held device cheaply, quickly diagnosis malaria 3Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 2Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 3Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 4Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 5Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 6Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 7Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 8Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 9Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 10
...
...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around ...
Biology Products: